Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.

Autor: Branella GM; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Lee JY; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Okalova J; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Molecular Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States., Parwani KK; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Alexander JS; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Arthuzo RF; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Fedanov A; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Yu B; Expression Therapeutics, Inc., Tucker, GA, United States., McCarty D; Expression Therapeutics, Inc., Tucker, GA, United States., Brown HC; Expression Therapeutics, Inc., Tucker, GA, United States., Chandrakasan S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States., Petrich BG; Expression Therapeutics, Inc., Tucker, GA, United States., Doering CB; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Molecular Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States., Spencer HT; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Molecular Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Nov 13; Vol. 14, pp. 1294555. Date of Electronic Publication: 2023 Nov 13 (Print Publication: 2023).